Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEAP1 CART With Enzalutamide in mCRPC
NCT06236139Phase 2Recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Nov 2024
- Primary completion
- Mar 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of anti-steap1 car t-cells in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Fred Hutchinson Cancer Center. Started Nov 2024; status: recruiting.
02
Drugs
anti-steap1 car t-cells
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06236139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06236139.